Department of Genitourinary Medical Oncology Research,
Division of Cancer Medicine,
Department of Genitourinary Medical Oncology Research, Division of Cancer Medicine
Nora Navone has not added Biography.
If you are Nora Navone and would like to personalize this page please email our Author Liaison for assistance.
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.
The Journal of clinical investigation Aug, 2008 | Pubmed ID: 18618013
Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model.
PloS one Mar, 2010 | Pubmed ID: 20360964
P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells.
Cell cycle (Georgetown, Tex.) Aug, 2010 | Pubmed ID: 20703082
Prioritizing genes associated with prostate cancer development.
BMC cancer Nov, 2010 | Pubmed ID: 21044312
Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2011 | Pubmed ID: 21343372
Modeling a lethal prostate cancer variant with small-cell carcinoma features.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2012 | Pubmed ID: 22156612
Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Bone Mar, 2012 | Pubmed ID: 22173053
Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.
PloS one , 2011 | Pubmed ID: 22194926
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2012 | Pubmed ID: 22298898
Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.
PloS one , 2012 | Pubmed ID: 22363599
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.
Leukemia Sep, 2012 | Pubmed ID: 22425892
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
The Prostate Nov, 2012 | Pubmed ID: 22457212
Arachidonic acid metabolism in human prostate cancer.
International journal of oncology Oct, 2012 | Pubmed ID: 22895552
Targeting fibroblast growth factor pathways in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2013 | Pubmed ID: 24052019
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Science signaling May, 2014 | Pubmed ID: 24847116
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Science translational medicine Sep, 2014 | Pubmed ID: 25186177
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.
Cancer Jul, 2015 | Pubmed ID: 25832466
Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.
Oncotarget Oct, 2015 | Pubmed ID: 26455377
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
Biomaterials Jan, 2016 | Pubmed ID: 26599623
Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Epigenetics 03, 2016 | Pubmed ID: 26890396
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Nature 02, 2017 | Pubmed ID: 28166537
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Cell reports 02, 2017 | Pubmed ID: 28228262
Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2017 | Pubmed ID: 28512172
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2018 | Pubmed ID: 29138344
An Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.
Cancer research 07, 2018 | Pubmed ID: 29769196
Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone.
Science translational medicine 08, 2018 | Pubmed ID: 30068572
Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
Oncogene 04, 2019 | Pubmed ID: 30532030
The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling.
Oncotarget Nov, 2018 | Pubmed ID: 30555629
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.
Biomaterials 03, 2019 | Pubmed ID: 30682644
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
Oncogene 06, 2019 | Pubmed ID: 30858546
ERR1 and PGC1α associated mitochondrial alterations correlate with pan-cancer disparity in African Americans.
The Journal of clinical investigation 03, 2019 | Pubmed ID: 30920960
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.
Science translational medicine 05, 2019 | Pubmed ID: 31142679
Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis.
Antioxidants & redox signaling 06, 2020 | Pubmed ID: 31861963
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 03, 2020 | Pubmed ID: 31941830
HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression.
Biomolecules 03, 2020 | Pubmed ID: 32197509
Fibroblast growth factors signaling in bone metastasis.
Endocrine-related cancer Jul, 2020 | Pubmed ID: 32369771
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2020 | Pubmed ID: 32576626
Myxovirus Resistance Protein 1 (MX1), a Novel HO-1 Interactor, Tilts the Balance of Endoplasmic Reticulum Stress towards Pro-Death Events in Prostate Cancer.
Biomolecules Jul, 2020 | Pubmed ID: 32640729
Lindsey K. Sablatura1,
Kristin M. Bircsak2,
Peter Shepherd3,
Karla Queiroz4,
Mary C. Farach-Carson1,5,6,
Pamela E. Constantinou1,7,
Anthony Saleh2,
Nora Navone3,
Daniel A. Harrington1,5,6
1Department of BioSciences, Rice University,
2, Mimetas US Inc,
3Department of Genitourinary Medical Oncology Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,
4, Mimetas B.V.,
5Department of Bioengineering, Rice University,
6Department of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center,
7Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유